Relationship of sorafenib plasma/serum concentration and its efficacy as well as adverse effects and its application in the treatment of hepatocellular carcinoma
10.13699/j.cnki.1001-6821.2015.17.027
- VernacularTitle:索拉菲尼血药浓度与疗效和不良反应的关系以及在肝细胞癌治疗应用
- Author:
Rui SHI
1
;
Ran LI
;
Bing-Qing ZHAO
;
Yuan-Yuan JIAO
;
Yan-Hua ZHANG
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科 恶性肿瘤发病机制及转化研究教育部重点实验室
- Keywords:
sorafenib;
therapeutic drug monitoring;
hepatocellular carci-noma;
hypertension;
hand foot skin reaction
- From:
The Chinese Journal of Clinical Pharmacology
2015;(17):1793-1795
- CountryChina
- Language:Chinese
-
Abstract:
Sorafenib , the new generation targeted kinase inhibitor , has been approved for the treatment of renal cell carcinoma , unresectable hepatocellular carcinoma as well as radioactive iodine resistant advanced thyroid carcinoma.Significant improvement in progression of free survival and overall survival had been achieved in multicenter double -blinded placebo-controlled clinical studies.Hypertension and hand foot skin re-action are its most common adverse reactions , which negatively affect pa-tients′quality of life , and sometimes lead to dose reduction or treatment interruption.Accumulated evidence suggest plasma sorafenib concentra-tion may be a biomarker for prognosis and adverse effect prediction.This article summarized the relevant literature and discussed the feasibility of implementing sorafenib therapeutic drug monitoring in clinical settings to guide treatment strategy and prevent severe adverse effect in hepatocellu-lar carcinoma treatment .
